XERS

Xeris Pharmaceuticals Inc

XERS, USA

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

https://www.xerispharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XERS
stock
XERS

Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS MarketBeat

Read more →
XERS
stock
XERS

Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$11.5

Analyst Picks

Strong Buy

4

Buy

1

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1,479.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-72.13 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.17 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

24.29 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 14.16% of the total shares of Xeris Pharmaceuticals Inc

1.

Vanguard Total Stock Mkt Idx Inv

(2.9699%)

since

2025/07/31

2.

iShares Russell 2000 ETF

(2.2569%)

since

2025/08/31

3.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0693%)

since

2025/07/31

4.

Fidelity Small Cap Index

(0.9279%)

since

2025/06/30

5.

Nuveen Quant Small Cap Equity R6

(0.8515%)

since

2025/07/31

6.

iShares Russell 2000 Growth ETF

(0.8238%)

since

2025/08/31

7.

CREF Stock R3

(0.54%)

since

2025/07/31

8.

Fidelity Extended Market Index

(0.5372%)

since

2025/07/31

9.

Heptagon Driehaus US Micro Cap Eq C$ Acc

(0.5353%)

since

2025/07/31

10.

Vanguard Russell 2000 ETF

(0.443%)

since

2025/07/31

11.

SPDR® S&P Pharmaceuticals ETF

(0.4146%)

since

2025/08/31

12.

Xtrackers S&P 500 Swap ETF 1C

(0.3971%)

since

2025/07/31

13.

Kennedy Micro Cap

(0.3701%)

since

2025/06/30

14.

State St Russell Sm Cap® Indx SL Cl I

(0.3143%)

since

2025/08/31

15.

Vanguard Health Care ETF

(0.2801%)

since

2025/07/31

16.

Nuveen Quant Small/Mid Cap Eq R6

(0.2577%)

since

2025/07/31

17.

Wellington Management Company LLP

(0.2473%)

since

2025/06/30

18.

Vanguard US Momentum Factor ETF

(0.2381%)

since

2025/06/30

19.

Schwab Small Cap Index

(0.2376%)

since

2025/07/31

20.

NT R2000 Index Fund - NL

(0.2247%)

since

2025/06/30

21.

Calamos Timpani Small Cap Growth I

(0.2225%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.0035

EPS Estimate

0.0067

EPS Difference

-0.0032

Surprise Percent

-47.7612%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.